Clinical Certificate


Date: Thursday 6th May 2021 – Friday 7th May 2021
Venue: The Radisson Park Inn Hotel, 4 Cheetham Hill Rd, Manchester, M4 4EW
Accommodation: The Radisson Park Inn Hotel, 4 Cheetham Hill Rd, Manchester, M4 4EW
(accommodation is bookable separately when you complete the online booking form)
Organised by: Professor Jo Neill and Dr Richard Drake


Thursday 6 May
09:45–10:15 Arrival, Registration and Coffee
10:15–10:20 Introduction
Professor Jo Neill (Manchester)
10:20–10:55 Causes of schizophrenia: Introduction to current thinking
Professor Shôn Lewis (Manchester)
10:55–11:45 Early intervention in psychosis and inflammation
Professor Rachel Upthegrove (Birmingham)
11:45–11:55 Q&A session
11:55–12:30 New trial data and clinical guidelines
Professor Shôn Lewis (Manchester)
12:30–12:40 Q&A session
12:45–13:30 Lunch in the Restaurant
13:30–14:20 Recent developments in the psychopharmacological understanding of schizophrenia
Professor Bill Deakin (Manchester)
14:20–14:30 Q&A session
14:30–15:20 Genetics of schizophrenia, pharmacogenomics and treatment response
Professor Liz Tunbridge (Oxford)
15:20–15:30 Q&A session
15:30–16:00 Refreshments and delegates split into 3 groups
16:00–17:30 Group Work – Split into three groups
Group A: Treatment Problems
Dr Richard Drake (Manchester)
Group B: Treatment Problems
Professor Rachel Upthegrove (Birmingham)
Group C: Treatment Problems
Professor David Owens (Edinburgh)
17:30 End of Thursday Sessions
Friday 7 May
08:30–08:45 Arrival and Coffee
08:45–09:45 Antipsychotics and relapse prevention in schizophrenia
09:45–10:00 Q&A session
10:00–10:30 Refreshments
10:30–11:15 Pharmacology of antipsychotic medication and adherence
Dr Richard Drake (Manchester)
11:15–11:30 Q&A session
11:30–12:30 Pharmacological strategies for treatment-resistant schizophrenia
12:30–12:45 Q&A session
12:45–13:35 Lunch in the Restaurant
13:35–14:45 EPS Update
Professor David Owens (Edinburgh)
14:45–15:15 Q&A session
15:15 Meeting ends. Return of evaluation forms

Last edited 4th June 2020

Learning Objectives

At the end of this module, the attendees will:

  • Be aware of current theories of the causes and neurochemistry of schizophrenia
  • Know the pharmacology of conventional and atypical drugs
  • Be aware of the clinical assessment of therapeutic and adverse effects
  • Have an opinion about relative benefits of conventional and atypical drugs
  • Be updated on guidelines and the social context of drug prescribing in schizophrenia
  • Know about issues in clinical trial design
  • Have had an opportunity to discuss difficult management problems with colleagues and experts
To register for the Clinical Certificate (i.e. commitment to attend 3 modules), please complete this form.

This module is eligible for 11 CPD hours which are subject to peer group review.

For further details contact Susan Chandler, BAP Executive Officer:

Feedback from 2019 Module

"Excellent course. Really well organised and a great atmosphere for learning. Lovely food and I learnt so much. Very good value for money – BAP runs the best courses around!"

"Excellently organised meeting, clinically applicable and kudos to presenters and organisers"

"Thank you for an excellent course, I will recommend to colleagues"

"Really enjoyable and insightful, I have learnt a lot and it was highly relevant/practical to my clinical work"

Print DOIs